Christopher G. Geissinger

San Diego
  • 12670 High Bluff Drive
  • San Diego, CA 92130
  • USA
Profile Experience

Christopher Geissinger is a counsel in the San Diego office and is a member of the Corporate Department.

Mr. Geissinger's practice includes: 

  • Emerging companies
  • Corporate governance
  • Public company representation
  • Venture financings
  • Private placements
  • Public offerings
  • Life sciences and technology industries




A selection of Mr. Geissinger’s representations include:

  • Ballast Point Brewing & Spirits in its proposed initial public offering and US$1.0 billion sale to Constellation Brands
  • Bonti, a neurotoxin-focused company founded by ex-Allergan executives, in its preferred stock financings totaling US$27 million led by Haohai Aesthetics, RBV Capital, City Hill Ventures, JMCR Partners, and HighLight Capital
  • ChemoCentryx, Inc., a biopharmaceutical company, in its US$64 million initial public offering
  • Conatus Pharmaceuticals, Inc., a biotechnology company, in its US$33 million Series B financing, US$10 million bridge financing, US$15 million credit facility, and US$66 million initial public offering
  • Crinetics, focused on endocrine disorders, in its US$40 million Series A financing and US$65 million Series B financing with 5AM Ventures, Versant Ventures, Vivo Capital, Perceptive, and RA Capital
  • Cubic Corporation, a technology-driven, market-leading global provider of innovative, mission-critical solutions, in follow-on public offerings and in corporate governance matters
  • Erasca, a company dedicated to advancing exceptional scientific approaches to erase cancer, in venture financings with investors including ARCH Venture Partners, Andreessen Horowitz, and Cormorant Asset Management and in corporate governance matters
  • Evoke Pharma, Inc., a pharmaceutical company, in its US$25 million initial public offering
  • Florida Gas Transmission Company, LLC, a natural gas transportation company, in its US$300 million Rule 144A private placement of senior notes
  • MeLLmo, a software company developing mobile apps, in its US$30 million Series C financing
  • Neurana, developing novel, non-opioid treatments for muscle spasms, in its US$60 million Series A financing led by Sofinnova Ventures, New Leaf Venture Partners, and Longitude Capital
  • Oncternal Therapeutics, focused on oncology, in its US$17 million Series C financing led by Shanghai Pharma and earlier Series A and Series B financings with angel investors
  • ViaSat, Inc., an innovator in communications technologies and services, in its US$575 million Rule 144A private placements of senior notes and its tender offer for US$275 million of its outstanding senior notes
  • Zavante, a clinical-stage biopharmaceutical company, in its Series A financing led by Frazier Healthcare Partners, Longitude Capital, and Aisling Capital
  • Zeno Pharmaceuticals in its preferred stock financings totaling US$147 million led by Matrix Capital and Viking Global Investors
  • A number of investment banks in public offerings of equity securities, including offerings by Acadia Pharmaceuticals, Aerie Pharmaceuticals, Ardea Biosciences, Arena Pharmaceuticals, Biocryst Pharmaceuticals, Clovis Oncology, GlycoMimetics, La Jolla Pharmaceutical Company, Retrophin, Sequenom, Tocagen, and Tracon Pharmaceuticals
Thought Leadership
  • Co-author, “Annual Meeting Handbook,” RR Donnelley   
  • Co-lecturer, “Term Sheet Negotiations,” UCSD Rady School of Management
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.